LUMIFY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LUMIFY (LUMIFY).
Selective alpha-1 adrenergic receptor agonist that causes vasoconstriction of conjunctival blood vessels, reducing redness.
| Metabolism | Not extensively metabolized; primarily excreted unchanged in urine. |
| Excretion | Primarily renal (60-70% unchanged), with biliary/fecal elimination accounting for the remainder. |
| Half-life | Approximately 2.5-3 hours (terminal) in adults; clinical context: duration of mydriasis may be shorter than half-life due to receptor binding. |
| Protein binding | Approximately 50-60% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Approximately 0.5 L/kg, indicating moderate distribution into tissues. |
| Bioavailability | Not applicable (ocular and nasal routes are locally active; systemic bioavailability is minimal and not therapeutically relevant). |
| Onset of Action | Ocular: mydriasis within 15-20 minutes post-instillation. |
| Duration of Action | Ocular: mydriasis lasting 1-3 hours; nasal: vasoconstriction up to 8 hours after administration. |
Instill 1 drop in the affected eye(s) every 6 to 8 hours as needed, not to exceed 4 drops per eye per day.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; use not recommended for children under 5 years. |
| Geriatric use | No specific dose adjustment required; use with caution due to potential for increased systemic absorption and adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LUMIFY (LUMIFY).
| Breastfeeding | Brimonidine is excreted in human milk following oral administration. The milk-to-plasma (M/P) ratio is unknown for ophthalmic use. Due to low systemic absorption after ocular instillation, the amount ingested by a nursing infant is expected to be minimal. However, caution is advised because of potential adverse effects in the infant, such as apnea, bradycardia, and hypotension. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for LUMIFY. |
| Teratogenic Risk | LUMIFY (brimonidine ophthalmic solution) belongs to FDA Pregnancy Category B. Animal studies have revealed no evidence of harm to the fetus, but there are no adequate and well-controlled studies in pregnant women. Due to minimal systemic absorption after ocular administration, risk is considered low. However, brimonidine is an alpha-2 adrenergic agonist; in third trimester, use cautiously due to potential for maternal hypotension and reduced uterine blood flow. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to brimonidine or any component","Angle-closure glaucoma","Patients with narrow-angle glaucoma","Children under 2 years of age"]
| Precautions | ["Do not use if solution changes color or becomes cloudy","Do not use with contact lenses","Overuse may cause increased redness (rebound hyperemia)","Discontinue if eye pain, vision changes, or continued redness occurs","Use with caution in patients with cardiovascular disease, hypertension, hyperthyroidism, or diabetes"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure and heart rate periodically due to potential systemic effects of brimonidine. In pregnant women, assess for signs of maternal hypotension and fetal heart rate monitoring is not routinely required but may be considered if maternal systemic effects occur. No routine fetal monitoring is mandated for ophthalmic use. |
| Fertility Effects | No adequate studies on fertility in humans. Animal studies have not shown impaired fertility at doses many times the human ocular dose. Given low systemic absorption, significant impact on fertility is unlikely. |